Survey about ovarian cancer treatments |
Cervical Cancer Treatment Survey
We understand that the manufacturer of AVASTIN, Hoffman-LaRoche, will be applying for approval from the pan-Canadian Oncology Drug Review (pCODR) in the near future for the use of bevacizumab (AVASTIN) in combination with chemotherapy for the treatment of patients with persistent, recurrent, or metastatic cervical cancer.
Bevacizumab, known by its brand name, AVASTIN, targets a cancer cell protein called vascular endothelial growth factor (VEGF). This protein helps cancers to grow blood vessels, so they can get food and oxygen from the blood. Information about AVASTIN and related side effects can be found on line at http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/cancer-drugs/bevacizumab.
As a component of the approval process, pCODR is interested in hearing from women living with cervical cancer. With no patient advocacy group for cervical cancer in Canada, Ovarian Cancer Canada is taking the lead on preparing a submission from women living with cervical cancer. The survey below will gather the input of women living with cervical cancer for this submission. Those eligible to fill out the survey are:
1) women who have been diagnosed with cervical cancer and who have been treated with chemotherapy; OR
2) women who have had a recurrence of cervical cancer and treated with additional chemotherapy; OR
3) women who have taken AVASTIN as a treatment for their cervical cancer.
In this survey, the word 'treatment' refers to chemotherapy drugs only and does not refer to surgery or radiation.
Information provided in this survey will be synthesized to form the submission. At times, we may use 'quotes', however, no names or identifiers will be used that could reveal your identity.
This survey should take approximately 20 minutes to complete. Thank you for your support.
Bevacizumab, known by its brand name, AVASTIN, targets a cancer cell protein called vascular endothelial growth factor (VEGF). This protein helps cancers to grow blood vessels, so they can get food and oxygen from the blood. Information about AVASTIN and related side effects can be found on line at http://www.cancerresearchuk.org/cancer-help/about-cancer/treatment/cancer-drugs/bevacizumab.
As a component of the approval process, pCODR is interested in hearing from women living with cervical cancer. With no patient advocacy group for cervical cancer in Canada, Ovarian Cancer Canada is taking the lead on preparing a submission from women living with cervical cancer. The survey below will gather the input of women living with cervical cancer for this submission. Those eligible to fill out the survey are:
1) women who have been diagnosed with cervical cancer and who have been treated with chemotherapy; OR
2) women who have had a recurrence of cervical cancer and treated with additional chemotherapy; OR
3) women who have taken AVASTIN as a treatment for their cervical cancer.
In this survey, the word 'treatment' refers to chemotherapy drugs only and does not refer to surgery or radiation.
Information provided in this survey will be synthesized to form the submission. At times, we may use 'quotes', however, no names or identifiers will be used that could reveal your identity.
This survey should take approximately 20 minutes to complete. Thank you for your support.